CORDRAN TAPE Rx
Generic Name and Formulations:
Indications for CORDRAN TAPE:
Adults and Children:
Clean and dry area before each use. Apply every 12hrs; may replace every 24hrs if tolerated.
Tape: Serum-exuding lesions. Intertrigo.
Treat infection if present; discontinue if infection persists or worsens. Avoid use near eyes. Systemic absorption increased by more potent steroids, prolonged use, use over large surface area, or use of occlusive dressings. Avoid abrupt cessation in chronic use. Occlude only if necessary; do not occlude higher potency products. Do not use tight-fitting diapers or plastic pants on patients. Do not use on face, groin, or axillae. Monitor adrenal function in children if a high potency product or occlusion is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. in children). Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infections, skin atrophy, striae, miliaria, other local effects; immunosuppression, masks infections, intracranial hypertension, HPA axis suppression (esp. in children).
Crm 0.025%—30g, 60g, 120g; Crm 0.05%—15g, 30g, 60g, 120g; Lotion—15mL, 60mL, 120mL; Oint 0.05%—15g, 30g, 60g; Tape (roll) 3in x 24in, 3in x 80in—1
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies